Christopher Enny

3.5k total citations
21 papers, 962 citations indexed

About

Christopher Enny is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Christopher Enny has authored 21 papers receiving a total of 962 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Christopher Enny's work include Lymphoma Diagnosis and Treatment (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Erythropoietin and Anemia Treatment (5 papers). Christopher Enny is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Multiple Myeloma Research and Treatments (5 papers) and Erythropoietin and Anemia Treatment (5 papers). Christopher Enny collaborates with scholars based in United States, United Kingdom and Canada. Christopher Enny's co-authors include Howard L. Corwin, Ronald G. Pearl, K. Dean Gubler, Michael J. Corwin, Robert M. Rodriguez, Andrew Gettinger, Theodore Colton, Helgi van de Velde, Wayne Langholff and Andrew Cakana and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Christopher Enny

21 papers receiving 942 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Enny United States	14	425	330	263	255	250	21	962
C. Tom Kouroukis Canada	18	383 0.9×	252 0.8×	151 0.6×	346 1.4×	460 1.8×	49	1.2k
Olga Meltem Akay Türkiye	15	274 0.6×	70 0.2×	37 0.1×	141 0.6×	106 0.4×	83	678
M. Troner United States	12	379 0.9×	83 0.3×	279 1.1×	101 0.4×	201 0.8×	19	1.1k
Jin‐Hou Wu Taiwan	19	604 1.4×	351 1.1×	47 0.2×	309 1.2×	169 0.7×	59	999
Ming‐Chung Kuo Taiwan	20	686 1.6×	379 1.1×	48 0.2×	361 1.4×	224 0.9×	84	1.2k
I. A. Cooper Australia	13	275 0.6×	40 0.1×	143 0.5×	140 0.5×	110 0.4×	27	636
Oscar Ballester United States	15	780 1.8×	320 1.0×	36 0.1×	162 0.6×	1.3k 5.1×	42	1.9k
Gregor Hron Austria	17	717 1.7×	190 0.6×	48 0.2×	103 0.4×	81 0.3×	31	1.2k
Peter Wood Australia	14	66 0.2×	95 0.3×	59 0.2×	394 1.5×	573 2.3×	36	1.1k
María Fernanda López Fernández Spain	20	894 2.1×	102 0.3×	45 0.2×	212 0.8×	10 0.0×	66	1.3k

Countries citing papers authored by Christopher Enny

Since Specialization

Citations

This map shows the geographic impact of Christopher Enny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Enny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Enny more than expected).

Fields of papers citing papers by Christopher Enny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Enny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Enny. The network helps show where Christopher Enny may publish in the future.

Co-authorship network of co-authors of Christopher Enny

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Enny. A scholar is included among the top collaborators of Christopher Enny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Enny. Christopher Enny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Freeman, Ciara L., Ling Jin, Sriram Balasubramanian, et al.. (2022). Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 36(10). 2479–2487. 3 indexed citations

Heß, Georg, Simon Rule, Wojciech Jurczak, et al.. (2017). Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leukemia & lymphoma. 58(12). 2824–2832. 15 indexed citations

Offner, Fritz, Olga Samoilova, Evgenii A. Osmanov, et al.. (2015). Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 126(16). 1893–1901. 98 indexed citations

Ludwig, Heinz, Richard Greil, Tamás Masszi, et al.. (2015). Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up. British Journal of Haematology. 171(3). 344–354. 21 indexed citations

Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2012). Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology. 31(2). 247–255. 58 indexed citations

Zinzani, Pier Luigi, Nuriet K. Khuageva, Huaqing Wang, et al.. (2012). Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. Journal of Hematology & Oncology. 5(1). 67–67. 17 indexed citations

Crump, M., Adriana Scheliga, Jiří Mayer, et al.. (2011). Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy. Annals of Oncology. 22. 186–186. 1 indexed citations

Dubrey, Simon W, Donna Reece, Vaishali Sanchorawala, et al.. (2011). Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM. 104(11). 957–970. 37 indexed citations

Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology. 12(8). 773–784. 81 indexed citations

10.

Reece, Donna, Ute Hegenbart, Vaishali Sanchorawala, et al.. (2011). Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 118(4). 865–873. 123 indexed citations

11.

Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2010). Phase II study of bortezomib, thalidomide, and dexamethasone /- cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): safety and activity including evaluation of MRD. 4 indexed citations

12.

Reece, DE, Ute Hegenbart, Vaishali Sanchorawala, et al.. (2010). Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study.. Journal of Clinical Oncology. 28(15_suppl). 8023–8023. 1 indexed citations

13.

Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2010). A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. Blood. 116(21). 857–857. 11 indexed citations

14.

Stowell, Christopher P., Stanley Jones, Christopher Enny, Wayne Langholff, & G Leitz. (2009). An Open-Label, Randomized, Parallel-Group Study of Perioperative Epoetin Alfa Versus Standard of Care for Blood Conservation in Major Elective Spinal Surgery. Spine. 34(23). 2479–2485. 65 indexed citations

15.

Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2009). Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.. Blood. 114(22). 2312–2312. 5 indexed citations

16.

Napolitano, Lena M., Timothy C. Fabian, Kathleen Kelly, et al.. (2008). Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin. The Journal of Trauma: Injury, Infection, and Critical Care. 65(2). 285–299. 56 indexed citations

17.

Lefèbvre, Patrick, Francis Vekeman, Brenda Sarokhan, et al.. (2006). Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Current Medical Research and Opinion. 22(10). 1929–1937. 55 indexed citations

18.

Corwin, Howard L., Andrew Gettinger, Robert M. Rodriguez, et al.. (2001). Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial*. Critical Care Medicine. 29(Supplement). S201–S205. 21 indexed citations

19.

Corwin, Howard L., Andrew Gettinger, Robert M. Rodriguez, et al.. (1999). Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Critical Care Medicine. 27(11). 2346–2350. 230 indexed citations

20.

Corwin, Howard L., Andrew Gettinger, Robert M. Rodriguez, et al.. (1998). EFFICACY OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE CRITICALLY ILL PATIENT. Critical Care Medicine. 26(Supplement). 23A–23A. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact